J Korean Soc Emerg Med.
2022 Apr;33(2):164-171.
BNT162b2 mRNA COVID-19 vaccine adverse reactions needing medical support: a vaccine center experience
- Affiliations
-
- 1Department of Emergency Medicine, National Medical Center, Seoul, Korea
- 2Division of Infection Diseases, National Medical Center, Seoul, Korea
- 3Department of Pediatrics, National Medical Center, Seoul, Korea
- 4Department of Anesthesia and Pain Medicine, National Medical Center, Seoul, Korea
- 5Department of Drug Safety Center, National Medical Center, Seoul, Korea
Abstract
Objective
The coronavirus disease 2019 (COVID-19) pandemic has not yet been controlled and herd immunity through vaccination against COVID-19 has been considered the best option to prevent the spread of COVID-19 worldwide. We encountered several patients in our emergency department presenting with adverse reactions after COVID-19 vaccinations. Hence, we investigated the clinical characteristics of patients with adverse reactions after vaccination.
Methods
In South Korea, 10,510 doses of the BNT162b2 mRNA COVID-19 vaccine was administered to 5,304 medical staff. To investigate adverse reactions, we reviewed the case report forms from the vaccination centers and the medical charts from the date of first dose administration until two weeks after the last planned second dose.
Results
A total of 187 cases, out of the 10,510, experienced adverse reactions and these were more common in females. Dizziness (44.4%), nausea and vomiting (28.3%), and fever (24.1%) were the most reported adverse reactions. Immediate adverse reactions included dizziness, nausea, and vomiting, palpitation, sensory changes, and delayed adverse reactions included fever, myalgia, headache, nausea, and vomiting. The delayed reactions of fever and myalgia were significantly more common after the second, rather than after the first dose (P<0.01 and P=0.03, respectively). One case of anaphylaxis was reported. All adverse reactions improved after conservative care.
Conclusion
Our findings show diverse adverse reactions to the BNT162b2 mRNA COVID-19 vaccine, but none of them required hospitalization. However, since this vaccine has been manufactured using a newly developed technique, more research focused on the clinical significance of the adverse reactions is necessary.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparison of Adverse Events of the First Dose and the Second Dose after Vaccination of the COVID-19 Pfizer Vaccine
- mRNA COVID-19 Vaccine-Associated Subserosal Eosinophilic Gastroenteritis: A Case Report
- Cutaneous Adverse Reaction After COVID-19 Vaccination
- Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea
- Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea
